Glioblastoma Multiforme Overview of Current Treatment and Future Perspectives
Glioblastoma Multiforme Overview of Current Treatment and Future Perspectives
复制标题
DOI：
10.1016/j.hoc.2012.04.006
复制
发表时间：
2012-08-01
影响因子：
2.4
通讯作者：
Mayer, Tina
中科院分区：
文献类型：
--
作者：
Anton, Kevin;Baehring, Joachim M.;Mayer, Tina
多形性胶质母细胞瘤是中枢神经系统最常见的原发性恶性肿瘤。尽管对胶质母细胞瘤病理生理有了新的认识，但诊断为这种高度侵袭性肿瘤的患者预后仍然黯淡。目前的治疗方案结合手术切除和放化疗，使中位总生存期从12.1个月增加到14.6个月。正在进行的临床前和临床研究评估新疗法的疗效，为提高生存效益提供了希望。本文综述了新诊断和复发性胶质母细胞瘤的治疗进展，包括抗血管生成药物、哺乳动物靶向雷帕霉素抑制剂、聚（adp -核糖）聚合酶-1抑制剂和免疫疗法等新疗法。
Glioblastoma multiforme is the most common primary malignant tumor of the central nervous system. Despite new insights into glioblastoma pathophysiology, the prognosis for patients diagnosed with this highly aggressive tumor remains bleak. Current treatment regimens combine surgical resection and chemoradiotherapy, providing an increase in median overall survival from 12.1 to 14.6 months. Ongoing preclinical and clinical studies evaluating the efficacy of novel therapies provide hope for increasing survival benefit. This article reviews the advancements in glioblastoma treatment in newly diagnosed and recurrent glioblastoma, including novel therapies such as antiangiogenic agents, mammalian target of rapamycin inhibitors, poly(ADP-ribose) polymerase-1 inhibitors, and immunotherapies.